Sectors
Share
Healthcare should see decent growth over the coming year, but rising vacancies could throw a spanner in the works
Tariffs won't bring the manufacturing of generic pharmaceuticals back to the US, but there are alternatives
The most vulnerable US citizens are those who could feel the biggest impact from incoming pharma tariffs
Our take on why ESG in healthcare is here to stay
By Diederik Stadig